Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, 5-week, open-label, randomized, multi-center, parallel-group study with a 20-week, open-label extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5 cm2 rivastigmine patch formulation in patients with probable Alzheimer's disease

Next Previous
Trial Profile

A prospective, 5-week, open-label, randomized, multi-center, parallel-group study with a 20-week, open-label extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5 cm2 rivastigmine patch formulation in patients with probable Alzheimer's disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWAP
  • Sponsors Novartis

    • Most Recent Events

    • 19 May 2009 Results presented at APA 2009.
    • 03 May 2008 Results presented at the 161st Annual Meeting of the American Psychiatric Association 2008.
    • 30 Apr 2008 Results reported at the Annual Scientific Meeting of the American Geriatrics Society (1112825)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top